Check out my latest article at MedCity News looking at how the advent of precision medicine will affect patients, regulators and payers.
The article describes how precision medicine will be good for patients. Precision medicines will likely be more expensive that regular therapies, but–because they are targeted to more specific populations–aggregate spending on pharmaceuticals could increase or decrease. The article also discusses challenges regulators face when determining the efficacy and safety of precision medicines.